Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1200P - A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial

Date

21 Oct 2023

Session

Poster session 13

Topics

Tumour Site

Neuroendocrine Neoplasms

Presenters

oOttavia Clemente

Citation

Annals of Oncology (2023) 34 (suppl_2): S701-S710. 10.1016/S0923-7534(23)01264-4

Authors

O. Clemente1, N. Starita2, A. Bracigliano3, M. Cives4, F. Tatangelo5, M.L. Barretta6, G. Badalamenti7, S. Lastoria3, F. Picozzi8, A. Di Mauro5, C. von Arx9, L. Cannella8, S. Tafuto8

Author affiliations

  • 1 Rare Tumors And Sarcomas Dept., Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 2 Uoc Biologia Molecolare E Oncogenesi Virale, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 3 Nuclear Medicine, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 4 Gi Oncology Department, Università degli Studi di Bari Aldo Moro, 70121 - Bari/IT
  • 5 Pathology Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 6 Radiology Department, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 7 Oncology Department, AOU Policlinico Paolo Giaccone, 90127 - Palermo/IT
  • 8 Sarcomas And Rare Tumors Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 9 Clinical Medicine And Surgery Department, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1200P

Background

Both CBZ and TMZ have already shown clinical efficacy in patients (pts) with NENs when used in monotherapy. Preclinical evidence demonstrated that downregulation of c-MET increases the sensitivity of glioblastoma cell lines to TMZ, and we hypothesized that CBZ could enhance the clinical efficacy of TMZ against NENs by inhibiting c-MET. The Cabotem trial aims at evaluating the efficacy and safety of CBZ in combination with TMZ as a treatment in lung and GEP-NENs progressive to SSAs, everolimus, sunitinib or PRRT.

Methods

This is a phase II, open-label, single-arm, multicentre study. Thirty-five pts were treated with CBZ (40 mg per os daily continuously) and TMZ 100 mg/m2/day (one week on/one week off). The primary endpoint was overall response rate (ORR) assessed by RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and 1-year OS.

Results

Of the 33 patients enrolled (M: 14, F: 19; pancreas:12; GI: 9; Lung: 8; UNK: 4), 25 are currently evaluable for response. After a median follow-up of 6 months, an ORR of 12% was recorded, with a clinical benefit rate (CR+PR+SD) of 72%. Ten patients prematurely discontinued the treatment (median: 3 months) due to severe adverse events (AEs). The most common G3/G4 treatment-related AEs were thrombocytopenia, palmar/plantar erythrodysesthesia, nausea, vomiting, appetite loss and dysgeusia.

Conclusions

The combination of CBZ and TMZ shows promising antitumor activity in patients with NENs. While tolerability appears to be an issue, the relatively high rate of toxicities observed in this study should be weighted against the characteristics of a heavily pretreated patient population.

Clinical trial identification

EudraCT 2020-001898-78.

Editorial acknowledgement

Legal entity responsible for the study

Istituto Nazionale Tumori IRCCS G. Pascale of Naples.

Funding

Ipsen.

Disclosure

C. von Arx: Financial Interests, Personal, Advisory Board, Receipt of consultation fees, Participation in a company sponsored speaker’s bureau: AstraZeneca; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Pierre-Fabre, Gentili, Lilly, Novartis, Ipsen; Financial Interests, Personal, Other, Conference Fee and travel grant: Organon; Financial Interests, Personal, Conference fee and travel grant: AAA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.